IMU Biosciences closed an expanded £40 million ($53.9 million) Series A round to scale its high-definition immune profiling technology. The financing follows an earlier January close and brings total raised since the company’s formation in 2021 to £45 million. IMU said it will use proceeds to support operations, infrastructure and clinical programs, including work in transplant rejection and immuno-oncology. The company claims it has built an unusually large high-definition immune system dataset, with nearly 25,000 profiles spanning healthy volunteers and disease cohorts. In practice, the data resource is intended to improve how immune phenotypes are characterized for translational biomarker development—an area where many oncology and transplant studies struggle to connect mechanism to clinical response. The round highlights ongoing capital investment into immunology measurement platforms as sponsors seek more predictive biomarkers and higher-resolution readouts for cell-based and immune-modulating therapies.